CRISPR Therapeutics Stock Falls 3.5% on Q3 Results

CRISPR Therapeutics Stock Falls 3.5% on Q3 Results

CRISPR Therapeutics (NASDAQ: CRSP) disappointed the market today with its third-quarter results, due in no small part to a dramatic but expected flip into the red on the bottom line. For similar reasons, CRISPR posted a loss in this most recent quarter.